Alliancebernstein L.P. Buys 4,560 Shares of Sotera Health (NASDAQ:SHC)

Alliancebernstein L.P. grew its stake in Sotera Health (NASDAQ:SHC) by 2.2% during the 4th quarter, HoldingsChannel reports. The fund owned 209,823 shares of the company’s stock after purchasing an additional 4,560 shares during the quarter. Alliancebernstein L.P.’s holdings in Sotera Health were worth $2,870,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of SHC. Pictet Asset Management Holding SA boosted its stake in Sotera Health by 29.1% during the 4th quarter. Pictet Asset Management Holding SA now owns 21,593 shares of the company’s stock valued at $295,000 after purchasing an additional 4,871 shares during the last quarter. Norges Bank purchased a new stake in shares of Sotera Health during the fourth quarter valued at $12,764,000. JPMorgan Chase & Co. boosted its position in shares of Sotera Health by 3.1% during the fourth quarter. JPMorgan Chase & Co. now owns 255,341 shares of the company’s stock valued at $3,493,000 after buying an additional 7,594 shares during the last quarter. WINTON GROUP Ltd purchased a new position in Sotera Health in the 4th quarter worth about $329,000. Finally, Prudential Financial Inc. lifted its stake in Sotera Health by 25.5% during the 4th quarter. Prudential Financial Inc. now owns 76,329 shares of the company’s stock valued at $1,044,000 after acquiring an additional 15,500 shares during the period. 91.03% of the stock is owned by hedge funds and other institutional investors.

Sotera Health Trading Down 1.1 %

Shares of NASDAQ:SHC opened at $10.50 on Wednesday. The stock’s 50-day simple moving average is $12.02 and its two-hundred day simple moving average is $13.44. The stock has a market capitalization of $2.98 billion, a price-to-earnings ratio of 42.00 and a beta of 1.88. Sotera Health has a 52-week low of $9.53 and a 52-week high of $17.08. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88.

Analysts Set New Price Targets

Separately, Barclays reduced their price target on shares of Sotera Health from $16.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, April 10th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $15.20.

Sotera Health Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.